TDTatiana Yu. Demidova

Tatiana Yu. Demidova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tatiana Yu. Demidova has a total of 346 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiovascular-kidney-metabolic syndrome and type 2 diabetes mellitus: from risk stratification to multidisciplinary patient management

    by T. Yu. Demidova, M. Ya. Izmailova, Т. Ю. Демидова, М. Я. Измайлова

    Type 2 diabetes mellitus (T2DM) is a key component of cardiovascular-kidney-metabolic (CKM) syndrome, an interconnected complex of metabolic disorders, chronic kidney disease (CKD), and cardiovascular disease (CVD). T2DM is characterized by chronic hyperglycemia resulting from insulin resistance and progressive impairment of insulin secretion and is closely associated with excess adiposity and adipose tissue dysfunction. The presence of T2DM substantially increases the risk of atherosclerotic cardiovascular disease, heart failure, and CKD; their coexistence is associated with accelerated progression of multiorgan involvement, increased hospitalization rates, disability, and premature mortality. This article reviews the current concept and staging classification of CKM syndrome and describes the criteria for stages 0–4, including the role of prediabetes, T2DM, metabolic risk factors, CKD, and subclinical and clinically manifest CVD. The main preventive and therapeutic approaches according to CKM syndrome stage are presented, including lifestyle modification, weight loss, control of glycemia, blood pressure, and lipid levels, use of glucagon-like peptide-1 receptor agonists, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors. Prospects for implementing a stage-based approach within the Russian healthcare system are discussed.

  • Composition of the gut microbiota in treatment-naive patients with newly diagnosed type 2 diabetes mellitus

    by T.YU. Demidova, K.G. Lobanova, A.S. Teplova

    Alterations in the gut microbiota (GM) are increasingly recognized as a key contributor to the pathogenesis of type 2 diabetes mellitus (T2DM). However, its taxonomic composition, as well as the structural characteristics of enterotypes (ETs) and microbiota-based cooperative networks, remain incompletely characterized. Objective. To characterize the GM composition in treatment-naïve patients with newly diagnosed T2DM. Material and methods. This observational study assessed GM composition using 16S rRNA gene amplicon sequencing. Enterotypes were identified by Dirichlet multinomial mixture modeling, and microbial cooperative networks were inferred using the SPIEC-EASI algorithm. Results. No significant differences were observed at the phylum, class, or order levels compared with reference populations. At the family level, Lachnospiraceae predominated over Bacteroidaceae. At the genus level, Bacteroides, Blautia, and Alistipes were dominant, while the species-level profile was characterized by a high relative abundance of Bacteroides vulgatus and Prevotella copri, along with numerous unclassified taxa. Three enterotypes were identified. ET-1 exhibited a mixed profile, including taxa negatively associated with T2DM and obesity (Faecalibacterium, Christensenella) and taxa positively associated with T2DM risk (Bacteroides). ET-2 was characterized by the predominance of Blautia and Bacteroides, taxa associated with metabolic dysregulation and atherosclerosis. ET-3 was enriched in Prevotella and Faecalibacterium and was associated with a more favorable metabolic profile. Four dominant microbial cooperative networks were identified, ranging from an adverse profile (MC-1, associated with T2DM, obesity, and atherosclerosis) to a potentially protective profile (MC-4, enriched in butyrate-producing taxa). Conclusion. In newly diagnosed, treatment-naïve T2DM, the GM is characterized by distinct taxonomic features and heterogeneity in enterotype structure and microbial networks. These findings may inform the development of microbiota-based predictive models.

  • Open Access

    Obesity as a global problem of the 21st century: Development mechanisms and modern management strategies

    by T. Yu. Demidova, M. Ya. Izmailova, N. A. Vartpatrikova

    Obesity as a global problem of the 21st century: Development mechanisms and modern management strategies | Demidova | FOCUS. Endocrinology Ожирение как глобальная проблема XXI века: механизмы развития и современные стратегии управления | Демидова | FOCUS Эндокринология

  • Open Access

    Evolution of concepts on optimal nutrition as a pillar for improving metabolic health

    by T. Yu. Demidova, I. G. Nikitin, A. V. Starodubova, O. A. Kislyak, M. Ya. Izmaylova

    Obesity is one of the most significant medical and social problems of our time, being the leading preventable cause of global morbidity and premature mortality. According to the results of large-scale epidemiological studies, over the past few decades the prevalence of this condition has taken on the characteristics of a pandemic of non-communicable diseases: the global prevalence of obesity has almost tripled, posing a serious challenge to healthcare systems in the 21st century and resulting in colossal economic losses. The updated dietary guidelines (Dietary Guidelines for Americans) marked the introduction of a fundamentally new visual model of nutrition, based on the concept of prioritising whole foods and strictly limiting ultraprocessed foods, which effectively led to the transformation of the traditional model into an ‘inverted’ pyramid focused on the nutritional density of the diet. In line with the current positions of leading global and domestic professional communities, the basis for successful treatment remains a comprehensive, personalised lifestyle modification, including dietary behaviour correction and regular physical activity. However, the priority use of innovative pharmacological agents – glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1 receptor agonists – is becoming a key driver and innovative breakthrough in modern evidence-based medicine.

  • Open Access

    The role of cardiovascular autonomic neuropathy in the development of cardiorenal complications in patients with type 2 diabetes mellitus

    by T. Yu. Demidova, M. Ya. Izmaylova, M. E. Shirnina, Т. Ю. Демидова, М. Я. Измайлова, М. Е. Ширнина

    Introduction. Among the most significant complications of diabetes mellitus (DM) is cardiovascular autonomic neuropathy (CAN) that is a serious but sometimes poorly recognised complication. Аim. To evaluate the prevalence of cardiovascular autonomic neuropathy (CAN) and its role in the development of chronic heart failure (CHF), chronic kidney disease (CKD) and atherosclerotic cardiovascular diseases (ACCD) in patients with type 2 diabetes mellitus (T2DM). Mat erials and methods. 80 patients with DM2 were examined. To diagnose CAN, each patient underwent a set of functional tests (Table 1), the patients were divided into 2 groups: with a confirmed diagnosis of CAN and without CAN. Clinical and anamnestic, laboratory data and a set of instrumental studies for the diagnosis of cardiorenal complications of diabetes were evaluated. A comparison of the prevalence, as well as the risk ratio for the main complications of type 2 diabetes has been carried out. Results. In the CAN group, heart failure (HF) was diagnosed significantly more frequently, occurring in 87.9% of cases compared to 59.5% in the group without CAN (p < 0.05). It was established that CAN correlates primarily with the development of heart failure with preserved ejection fraction (HFpEF): 78.8% vs. 34.0% (p < 0.05). Differences in the prevalence of chronic kidney disease and atrial fibrillation showed borderline significance. The presence of CAN increases the risk of developing HF nearly fivefold (RR = 4.92; p = 0.001), and the risk of HFpEF more than fivefold (RR = 5.50; 95% CI: 4.16–7.92; p = 0.0001). Conclusion. In the present study, almost every second patient with DM2 had an undiagnosed CAN. The presence of CAN increased the chances of developing CHF by more than 5 times, while there was no significant effect on the risk of developing CHF with reduced and moderately reduced LV (CHF/nFV). Despite the growing understanding of the role of CAN, its prognostic significance and mechanisms in the development of specific cardiorenal complications remain the subject of active research.

  • Influence of dietary patterns on gut microbiota metabolism in patients with type 2 diabetes mellitus

    by T.YU. Demidova, A.S. Teplova, P.A. Chernukha, E.V. Stepanova, E.YU. Moiseeva

    Adherence to balanced dietary principles as part of a healthy lifestyle is of increasing importance. The wide range of dietary patterns offers considerable flexibility, enabling individualized dietary approaches. Of particular interest is the effect of different dietary patterns on gut microbiota (GM) metabolism and the potential to apply these insights to optimize the management of metabolic disorders, especially type 2 diabetes mellitus (T2DM). Objective: To evaluate the effects of various dietary patterns on GM metabolism in patients with T2DM. Key points. This review is based on contemporary literature retrieved from PubMed, Google Scholar, MEDLINE, and eLibrary. It addresses both therapeutic diets aimed at secondary prevention and reduction of complication risk, as well as widely adopted dietary patterns in the general population used for health promotion. Diets with limited evidence and questionable benefits are also discussed. The effects of dietary patterns on GM metabolism in T2DM are examined in terms of predominant and restricted dietary components, with particular attention to their impact on glycemic control, lipid profile, body weight, cardiovascular status, and key pathogenic pathways of T2DM. Conclusion: Currently, there is no consensus on dietary recommendations for T2DM, which limits their clinical applicability. A better understanding of diet–GM interactions may support the development of personalized nutritional strategies for patients with T2DM.

  • Polycystic ovary syndrome through the prism of cardiometabolic risk: From pathogenesis to new therapeutic strategies

    by F. O. Ushanova, T. Yu. Demidova

    Polycystic ovary syndrome (PCOS) is considered a complex multisystem condition with a pronounced cardiometabolic profile in modern medicine. Traditional therapeutic strategies based on combined oral contraceptives and metformin are often insufficiently effective for long-term correction of metabolic risks and prevention of cardiovascular complications. This article discusses the paradigm shift in PCOS treatment, favoring the use of incretin agents – GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide). The multifaceted mechanism of action of these agents is analyzed, including not only weight loss and insulin resistance but also a direct impact on the pathophysiological components of the disease: hyperandrogenism, systemic inflammation, and ovarian dysfunction. The paper presents data from recent meta-analyses confirming significant improvements in anthropometric parameters and lipid profiles in PCOS under the influence of incretins. Integrating incretin therapy into PCOS management algorithms opens new possibilities for comprehensive metabolic and reproductive rehabilitation of patients, providing a personalized approach to the treatment of this heterogeneous disease.